Treatment Plans

Evidence-based clinical decision support for pediatric abdominal pain

Treatment Plans

Evidence-based management protocols including pharmacological and non-pharmacological interventions, dietary advice, follow-up schedules, and referral criteria.

Pharmacological Management

DrugDoseDurationNotes
Hyoscine butylbromide10mg TDS (>6 years)2-4 weeks trialFirst-line antispasmodic
Peppermint oil capsules187mg TDS (>8 years)2-4 weeksFor IBS symptoms
Amitriptyline10-20mg nocte3-6 monthsLow-dose TCA for refractory cases
Probiotics (Lactobacillus GG)10⁹-10¹⁰ CFU daily4-8 weeksEspecially for IBS

Non-Pharmacological Interventions

  • Cognitive Behavioral Therapy (CBT)
  • Gut-directed hypnotherapy
  • Relaxation techniques and guided imagery
  • Regular physical activity
  • Maintain normal school attendance
  • Symptom diary to identify triggers

Dietary Advice

  • Low FODMAP diet trial (6-8 weeks) for IBS
  • Adequate fiber intake (age + 5g/day)
  • Regular meal times
  • Adequate hydration
  • Limit carbonated drinks and caffeine
  • Consider lactose-free trial if symptoms suggest intolerance

Follow-up

Review in 2-4 weeks. If no improvement after 8 weeks of multimodal therapy, consider referral to pediatric gastroenterologist.

Referral Criteria

  • Failure to respond to 8 weeks of treatment
  • Diagnostic uncertainty
  • Significant school absence (>2 weeks)
  • Severe psychological comorbidity

Key Patient Education Points

  • Functional pain is REAL pain - it is not imagined or 'in their head'
  • The gut-brain connection explains why stress worsens symptoms
  • Goal is return to normal function, not necessarily complete pain elimination
  • Reassurance: functional pain does NOT indicate serious disease
  • Most children improve with time and appropriate management
  • Avoid reinforcing sick role - encourage normal activities

Note: Drug doses are guidelines only. Always verify doses using local formulary (e.g., BNF for Children) and adjust for individual patient factors including weight, renal/hepatic function, and drug interactions. Source: DynaMed Evidence-Based Guidelines.